Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · breast-umap@18

SRR8518171

— · A

d755ddc3-97f3-54bf-a0cf-0aaee8690dc8

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
A
subtype
A

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.620
  • ANGIOGENESIS+0.480
  • TGF_BETA_SIGNALING+0.450
  • OXIDATIVE_PHOSPHORYLATION+0.420
  • PANCREAS_BETA_CELLS+0.400
  • COAGULATION+0.370
  • PROTEIN_SECRETION+0.360
  • COMPLEMENT+0.280
  • APOPTOSIS+0.240
  • KRAS_SIGNALING_UP+0.240

Top 10 suppressed

  • MYC_TARGETS_V2-0.550
  • ESTROGEN_RESPONSE_EARLY-0.370
  • E2F_TARGETS-0.300
  • G2M_CHECKPOINT-0.300
  • MYC_TARGETS_V1-0.300
  • ESTROGEN_RESPONSE_LATE-0.250
  • CHOLESTEROL_HOMEOSTASIS-0.200
  • SPERMATOGENESIS-0.170
  • KRAS_SIGNALING_DN-0.160
  • BILE_ACID_METABOLISM-0.150

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1MBCProject_0419_T2_RNA
breast-umap@18
—A0.788
2TCGA-E9-A22E-01A-11R-A157-07
breast-umap@18
—A0.773
3TCGA-E9-A1NF-01A-11R-A14D-07
breast-umap@18
—C0.771
4TCGA-38-4627-01A-01R-1206-07
lung-landscapes@6
—cohortA10.757
5SRR25617929
breast-umap@18
—A0.754
6SRR8518419
breast-umap@18
—A0.753
7TCGA-E9-A1NG-01A-21R-A14M-07
breast-umap@18
—A0.752
8MBCProject_0857_T3_RNA
breast-umap@18
—A0.749
9C3L-00009
lung-landscapes@6
—cohortA10.748
10SRR8518186
breast-umap@18
—A0.747

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 31 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
EPITHELIAL_MESENCHYMAL_TRANSITION0.620Inavolisib— uncovered
ANGIOGENESIS0.480Remibrutinib— uncovered
TGF_BETA_SIGNALING0.450Inavolisib— uncovered
OXIDATIVE_PHOSPHORYLATION0.420Remibrutinib— uncovered
PANCREAS_BETA_CELLS0.400Cobimetinib— uncovered
COAGULATION0.370Binimetinib— uncovered
PROTEIN_SECRETION0.360Remibrutinib— uncovered
COMPLEMENT0.280Inavolisib— uncovered
APOPTOSIS0.240Idelalisib— uncovered
KRAS_SIGNALING_UP0.240Inavolisib— uncovered
UV_RESPONSE_DN0.230Inavolisib— uncovered
IL6_JAK_STAT3_SIGNALING0.190Inavolisib— uncovered
NOTCH_SIGNALING0.190Inavolisib— uncovered
MYOGENESIS0.180Inavolisib— uncovered
INFLAMMATORY_RESPONSE0.170Idelalisib— uncovered
HEDGEHOG_SIGNALING0.160Inavolisib— uncovered
HYPOXIA0.160Idelalisib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.160Inavolisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.150Inavolisib— uncovered
GLYCOLYSIS0.140Inavolisib— uncovered